Tags

Type your tag names separated by a space and hit enter

Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma.
Am J Respir Crit Care Med. 1995 Oct; 152(4 Pt 1):1198-202.AJ

Abstract

The involvement of platelet-activating factor (PAF) in bronchial hyperresponsiveness (BHR) in bronchial asthma has been controversial. To determine whether PAF is involved in BHR in humans, we carried out a randomized, double-blind, placebo-controlled, two-phase cross-over study on the effects of Y-24180, a potent, specific, orally active PAF receptor antagonist, on BHR to methacholine in patients with asthma. The subjects were 13 patients with extrinsic stable asthma. The provocative concentration of methacholine producing a 20% fall in FEV1 (PC20-FEV1) was measured as an index of BHR. Y-24180 (20 mg twice a day) or a placebo was orally administered for 2 wk, respectively. At the time of cross-over from the first treatment regimen to the second regimen, administration of the test drug was suspended for 2 wk. The methacholine challenge test was performed four times, before and after the first treatment period and before and after the second treatment period. Compared with the placebo, Y-24180 significantly (p = 0.005) improved the PC20-FEV1 value without carryover effect and period effect by analysis of variance. These results suggest that PAF is an important mediator involved in the BHR of bronchial asthma in humans.

Authors+Show Affiliations

2nd Department of Internal Medicine, Hiroshima University School of Medicine, Japan.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

7551370

Citation

Hozawa, S, et al. "Effects of a PAF Antagonist, Y-24180, On Bronchial Hyperresponsiveness in Patients With Asthma." American Journal of Respiratory and Critical Care Medicine, vol. 152, no. 4 Pt 1, 1995, pp. 1198-202.
Hozawa S, Haruta Y, Ishioka S, et al. Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. Am J Respir Crit Care Med. 1995;152(4 Pt 1):1198-202.
Hozawa, S., Haruta, Y., Ishioka, S., & Yamakido, M. (1995). Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. American Journal of Respiratory and Critical Care Medicine, 152(4 Pt 1), 1198-202.
Hozawa S, et al. Effects of a PAF Antagonist, Y-24180, On Bronchial Hyperresponsiveness in Patients With Asthma. Am J Respir Crit Care Med. 1995;152(4 Pt 1):1198-202. PubMed PMID: 7551370.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of a PAF antagonist, Y-24180, on bronchial hyperresponsiveness in patients with asthma. AU - Hozawa,S, AU - Haruta,Y, AU - Ishioka,S, AU - Yamakido,M, PY - 1995/10/1/pubmed PY - 1995/10/1/medline PY - 1995/10/1/entrez SP - 1198 EP - 202 JF - American journal of respiratory and critical care medicine JO - Am. J. Respir. Crit. Care Med. VL - 152 IS - 4 Pt 1 N2 - The involvement of platelet-activating factor (PAF) in bronchial hyperresponsiveness (BHR) in bronchial asthma has been controversial. To determine whether PAF is involved in BHR in humans, we carried out a randomized, double-blind, placebo-controlled, two-phase cross-over study on the effects of Y-24180, a potent, specific, orally active PAF receptor antagonist, on BHR to methacholine in patients with asthma. The subjects were 13 patients with extrinsic stable asthma. The provocative concentration of methacholine producing a 20% fall in FEV1 (PC20-FEV1) was measured as an index of BHR. Y-24180 (20 mg twice a day) or a placebo was orally administered for 2 wk, respectively. At the time of cross-over from the first treatment regimen to the second regimen, administration of the test drug was suspended for 2 wk. The methacholine challenge test was performed four times, before and after the first treatment period and before and after the second treatment period. Compared with the placebo, Y-24180 significantly (p = 0.005) improved the PC20-FEV1 value without carryover effect and period effect by analysis of variance. These results suggest that PAF is an important mediator involved in the BHR of bronchial asthma in humans. SN - 1073-449X UR - https://www.unboundmedicine.com/medline/citation/7551370/Effects_of_a_PAF_antagonist_Y_24180_on_bronchial_hyperresponsiveness_in_patients_with_asthma_ L2 - http://www.atsjournals.org/doi/full/10.1164/ajrccm.152.4.7551370?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -